Device type · GFO
Activated Partial Thromboplastin
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
GFO
Hematology
Device class
Class II
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
19
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Activated Partial Thromboplastin
- Product code
- GFO
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7925
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for GFO
Latest FDA decisions
Instrumentation Laboratory (IL) Co.
K253957 · Decided Jan 9, 2026 · 30 days after receipt
Device type: Activated Partial Thromboplastin (GFO) · Laboratory Medicine & Pathology
- Cryocheck Hex LA510(k)
K193556 · Decided Oct 23, 2020 · 305 days after receipt
Device type: Activated Partial Thromboplastin (GFO) · Laboratory Medicine & Pathology
K160445 · Decided Mar 16, 2016 · 28 days after receipt
Device type: Activated Partial Thromboplastin (GFO) · Laboratory Medicine & Pathology
Reports received
19
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
19
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 1 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 1 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 1 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 4 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 1 | 0 | 0 | 0 |
| Dec 25 | 6 | 0 | 0 | 0 |
| Jan 26 | 1 | 0 | 0 | 0 |
| Feb 26 | 1 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 2 | 0 | 0 | 0 |
| May 26 | 3 | 0 | 0 | 0 |
| Jun 26 | 3 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 1 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Device Ingredient or Reagent Problem10
- Microbial Contamination of Device6
- Break1
3 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions18
- Insufficient Information1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring of heparin therapy.Open, Classified
Z-1095-2026 · Started Dec 11, 2025 · Posted by FDA Jan 15, 2026
Reason given: Potential for microbial contamination.
Cause as FDA categorized it: Under Investigation by firm
- HemosIL SynthAFax. Partial Thromboplastin Time Tests.Open, Classified
Z-0938-2026 · Started Nov 18, 2025 · Posted by FDA Dec 17, 2025
Reason given: Recalled lots were manufactured with double the amount of preservative concentration.
Cause as FDA categorized it: Process control
Z-1108-2021 · Started Jan 5, 2021
Reason given: Intermittent potential for shorter than expected clot times.
Cause as FDA categorized it: Under Investigation by firm
7 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.